Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterolemia
NCT02890992Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2016
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Sanofi. Primary endpoint: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at 8 weeks. Started Sep 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT02890992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02890992.